A Phase 2 interventional study of Hydroxychloroquine in COVID-19, sponsored by Samah Lutfy. Status unknown at 1 site in Saudi Arabia. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2020-05-19.
Sponsored by Samah Lutfy · Phase 2, Interventional, and Treatment
Many reports argued about the possible beneficial effects of Hydroxychloroquine in treating COVID-19 patients and this study was designed to investigate this claim
7,640 studies on the registry are indexed under COVID-19; 488 are open to participants now.
This study's planned enrollment of 200 is above the median of 100 across 4,099 interventional studies indexed under COVID-19.
Browse COVID-19 studies →This is the only study on the registry with Samah Lutfy as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Confirmed cases of SARS-CoV-2 by PCR
Exclusion Criteria:
less than 18 years old known hypersensitivity to the drug
Drug: Hydroxychloroquine
400mg BD first day then 200 mg BD for 5 days
time to viral clearance
PCR will be done every 72 h day till 2 consecutive negative PCR tests(24h apart) which is the viral clearance.The time between randomization and viral clearance is the viral clearance time
Time frame: 21 days after patients randomization
% of mortality
total number of deaths divided by total number of the group
Time frame: 60 days after randomization
Length of stay
time from patients randomization till discharge
Time frame: 60 days after randomization
time to be afebrile
time from randomization till day of fever subsiding
Time frame: 60 days after randomization
need for mechanical ventilation
%of deteriorated patients necessitates mechanical ventilation
Time frame: 60 days after randomization
This study is status unknown, as verified in May 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.